209 related articles for article (PubMed ID: 10962341)
1. Tumor-induced osteomalacia and the regulation of phosphate homeostasis.
Kumar R
Bone; 2000 Sep; 27(3):333-8. PubMed ID: 10962341
[TBL] [Abstract][Full Text] [Related]
2. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia.
Kumar R
Curr Opin Nephrol Hypertens; 2002 Sep; 11(5):547-53. PubMed ID: 12187320
[TBL] [Abstract][Full Text] [Related]
3. FGF23, hypophosphatemia, and rickets: has phosphatonin been found?
Strewler GJ
Proc Natl Acad Sci U S A; 2001 May; 98(11):5945-6. PubMed ID: 11371627
[No Abstract] [Full Text] [Related]
4. What have we learnt about the regulation of phosphate metabolism?
Blumsohn A
Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):397-401. PubMed ID: 15199289
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.
Fukumoto S; Yamashita T
Curr Opin Nephrol Hypertens; 2002 Jul; 11(4):385-9. PubMed ID: 12105387
[TBL] [Abstract][Full Text] [Related]
6. Inorganic phosphate homeostasis and the role of dietary phosphorus.
Takeda E; Yamamoto H; Nashiki K; Sato T; Arai H; Taketani Y
J Cell Mol Med; 2004; 8(2):191-200. PubMed ID: 15256067
[TBL] [Abstract][Full Text] [Related]
7. PHEX gene and hypophosphatemia.
Drezner MK
Kidney Int; 2000 Jan; 57(1):9-18. PubMed ID: 10620182
[TBL] [Abstract][Full Text] [Related]
8. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
Bowe AE; Finnegan R; Jan de Beur SM; Cho J; Levine MA; Kumar R; Schiavi SC
Biochem Biophys Res Commun; 2001 Jun; 284(4):977-81. PubMed ID: 11409890
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic osteomalacia: is there a new phosphate regulating hormone?
Nelson AE; Robinson BG; Mason RS
Clin Endocrinol (Oxf); 1997 Dec; 47(6):635-42. PubMed ID: 9497867
[TBL] [Abstract][Full Text] [Related]
10. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
11. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
12. Phosphatonins: From Discovery to Therapeutics.
Kritmetapak K; Kumar R
Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
[TBL] [Abstract][Full Text] [Related]
13. Phosphate wasting in oncogenic osteomalacia: PHEX is normal and the tumor-derived factor has unique properties.
Nelson AE; Hogan JJ; Holm IA; Robinson BG; Mason RS
Bone; 2001 Apr; 28(4):430-9. PubMed ID: 11336925
[TBL] [Abstract][Full Text] [Related]
14. FGF23 and disorders of phosphate homeostasis.
Yu X; White KE
Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
Drezner MK; Lyles KW; Haussler MR; Harrelson JM
J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
[TBL] [Abstract][Full Text] [Related]
16. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype.
Erben RG; Mayer D; Weber K; Jonsson K; Jüppner H; Lanske B
J Bone Miner Res; 2005 Jul; 20(7):1149-60. PubMed ID: 15940367
[TBL] [Abstract][Full Text] [Related]
18. Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia.
Rowe PS
Hum Genet; 1994 Nov; 94(5):457-67. PubMed ID: 7959677
[TBL] [Abstract][Full Text] [Related]
19. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
20. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
